Brii Biosciences Limited Stock
Stocks
2137
KYG1645A1094
Biotechnology & Medical Research
OTC Markets Traded|
Market Closed -
Hong Kong S.E.
12:08:52 06/11/2026 +04
|
5-day change | 1st Jan Change | ||
| 1.040 HKD | +1.46% |
|
+7.22% | -26.24% |
| 10-16 | Brii Biosciences Launches siRNA Therapeutics Discovery Platform | MT |
| 10-15 | Brii Biosciences Limited Unveils BRiSC?, An siRNA Therapeutics Discovery Platform | CI |
| Market Cap | 639M 751M 95.72M 85.3M 78.02M 71.05M 134M 9.05B 138M 937M 375M 4.79B 359M 352M 15.12B | P/E 2024 |
-1.32x | P/E 2025 | -4.11x |
|---|---|---|---|---|---|
| Enterprise Value | -1.29B -1.52B -194M -173M -158M -144M -271M -18.3B -278M -1.9B -758M -9.69B -727M -711M -30.58B | EV / Sales 2024 |
-32.4x | EV / Sales 2025 | -28.6x |
| Free-Float |
93.28% | Yield 2024 * |
-
| Yield 2025 | - |
| Markets | Quality | ||
|---|---|---|---|
Hong Kong S.E.
| 2137 | Delayed | |
Tradegate
| 7SS | Real-time | |
|
Deutsche Boerse AG
| 7SS | Delayed | |
|
Börse Stuttgart
| 7SS | Delayed | |
|
Boerse Muenchen
| 7SS | Real-time |
Last Transcript: Brii Biosciences Limited
| 1 day | +1.46% | ||
| 1 week | +7.22% | ||
| Current month | +6.12% | ||
| 1 month | +19.54% | ||
| 3 months | +11.83% | ||
| 6 months | -21.80% | ||
| Current year | -26.24% |
| 1 week | 0.96 |  | 1.08 |
| 1 month | 0.82 | | 1.08 |
| Current year | 0.82 | | 1.7 |
| 1 year | 0.82 | | 1.9 |
| 3 years | 0.8 | | 3.5 |
| 5 years | 0.8 | | 48.65 |
| 10 years | 0.8 | | 52.6 |
| Manager | Title | Age | Since |
|---|---|---|---|
Zhi Hong
CEO | Chief Executive Officer | 62 | 23/02/2018 |
An Kang Li
DFI | Director of Finance/CFO | 48 | 01/09/2020 |
Brian Johns
CTO | Chief Tech/Sci/R&D Officer | - | 03/01/2024 |
| Director | Title | Age | Since |
|---|---|---|---|
Zhi Hong
CHM | Chairman | 62 | 24/03/2021 |
Martin Murphy
BRD | Director/Board Member | 83 | 22/06/2021 |
Hui Tang
BRD | Director/Board Member | 66 | 22/06/2021 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 24/09/26 | Other | Chief Financial Officer | -43,500 | 0.0059% | ||
| 21/09/26 | Other | Chief Executive Officer | -24,172 | 0.0033% | ||
| 27/08/26 | Other | Chief Financial Officer | -1,500 | 0.0002% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.46% | +7.22% | -43.78% | -60.00% | 94.34M | |
| -4.83% | +2.88% | +55.87% | +69.12% | 69.4B | |
| -0.47% | +0.64% | +10.17% | +75.92% | 57.24B | |
| -1.19% | +3.10% | +24.94% | +100.42% | 57.62B | |
| +1.71% | +0.81% | +27.81% | +35.84% | 43.65B | |
| +5.14% | +9.97% | +22.53% | +107.63% | 44.03B | |
| +6.87% | -2.12% | +205.08% | +769.36% | 38.08B | |
| -1.86% | +11.46% | +26.67% | +61.40% | 36.31B | |
| -2.97% | -9.84% | +88.86% | +76.17% | 32.61B | |
| -2.18% | +5.68% | +36.21% | -0.69% | 25.47B | |
| Average | +0.18% | +2.58% | +45.44% | +123.52% | 40.45B | |
| Weighted average by Cap. | -0.20% | +2.44% | +51.16% | +136.51% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 49.94M 58.7M 7.49M 6.67M 6.1M 5.56M 10.47M 707M 10.76M 73.29M 29.31M 375M 28.1M 27.49M 1.18B | 35.55M 41.79M 5.33M 4.75M 4.34M 3.96M 7.46M 504M 7.66M 52.18M 20.86M 267M 20M 19.57M 842M |
| Net income | -508M -597M -76.17M -67.88M -62.08M -56.54M -107M -7.2B -109M -746M -298M -3.81B -286M -280M -12.03B | -223M -262M -33.37M -29.74M -27.2M -24.77M -46.69M -3.15B -47.95M -327M -131M -1.67B -125M -123M -5.27B |
| Net Debt | -2.29B -2.69B -344M -306M -280M -255M -481M -32.47B -494M -3.36B -1.35B -17.2B -1.29B -1.26B -54.26B | -1.93B -2.27B -289M -258M -236M -215M -405M -27.35B -416M -2.83B -1.13B -14.48B -1.09B -1.06B -45.7B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 06/11/26 | HK$1.040 | +1.46% | 884,000 |
| 05/11/26 | HK$1.025 | 0.00% | 839,000 |
| 04/11/26 | HK$1.025 | +4.59% | 1,020,000 |
| 03/11/26 | HK$0.9800 | -2.49% | 773,000 |
| 02/11/26 | HK$1.005 | +2.55% | 512,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- 2137 Stock
Select your edition
All financial news and data tailored to specific country editions
